With Rova-T killed, spotlight shifts to AbbVie’s hematology, immunology franchises

The final clinical failure of a program AbbVie once regarded as the "anchor asset" in its solid tumor portfolio leaves AbbVie with little or nothing to show for its acquisition of Stemcentrx in 2016 for $5.8 billion up front.

Without any of the nearly $5 billion in peak annual revenues it hoped to gain from sales of antibody-drug conjugate Rova-T rovalpituzumab tesirine, the

Read the full 620 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE